Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AIM-IT: Intrathecal Idursulfase for Hunter Syndrome
NCT02055118Phase 3Completed
- Sponsor
- Takeda
- Start
- Mar 2014
- Primary completion
- Sep 2017
- Modality
- Replacement Enzymes
- Countries
- 7
01
Overview
Phase 3, randomised, open-label trial of idursulfase in mucopolysaccharidosis type II (2 arms), sponsored by Takeda. Primary endpoint: Differential Ability Scales, Second Edition General Conceptual Ability Standard Score at 52 weeks. Started Mar 2014; status: completed.
02
Drugs
idursulfase
03
Conditions
mucopolysaccharidosis type II
Beyond the preview
Go deeper on NCT02055118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02055118.